Strykerの空売り状況は、投資家がStrykerの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Stryker (NYSE:SYK) 株価情報, 空売り情報

Stryker

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

Stryker Corp

SOLITON SYSTEMS KK ORD by Soliton Systems

Soliton Systems KK

SKY NETWORK TV by Sky Network Television Ltd.

Sky Network Television Ltd

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), saying it's &#8220;just a gem&#8221; and a &#8220;winner.&#8221; &nbsp;He added, &#8220;I can't believe the stock dropped so much.&#8221;
On Jan. 31, AbbVie reported fourth-quarter adjusted earnings per share of $2.16, beating the street view of $2.11. Quarterly sales of $15.102 billion, outpacing the analyst consensus estimate of $14.827 billion. Several analysts also raised their price targets on the stock following the earnings announcement.
<h3 class="wp-block-heading">Cramer Shares His Views On These Tech Stocks</h3>
MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) is a trade and not an investment, Cramer said. &#8220;You'd be catching it at the right time. I think the analysts are all starting to upgrade the, the enterprise software again. I think it's worth a stab, I really do.&#8221;
In the recent news, MongoDB has partnered with Lombard Odier to modernize core banking technology with generative AI.
The Mad Money host recommended pulling the trigger on Cerence Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>).
On the earnings front, Cerence is scheduled to announce its first quarter financial results on Thursday, Feb. 6.
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
Cramer recommended buying Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) instead of going with Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>).
Supporting his view, Keefe, Bruyette &amp; Woods analyst Kyle Voigt, on Jan. 13, maintained Coinbase with a Market Perform and lowered the price target from $275 to $255.
Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) is the better one, Cramer said when asked about Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>). &#8220;If you want AI, then you go with Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>).&#8221;
Supporting that view, Loop Capital analyst Mark Schappel, on Jan. 14, maintained Tempus AI with a Buy and lowered the price target from $57 to $52.
Price Action:
<ul>
<li>MongoDB shares gained 2.7% to settle at $275.97 on Tuesday.</li>
<li>Tempus shares gained 0.5% to close at $61.85 during the session.</li>
<li>Coinbase shares fell 1.4% to settle at $280.39.</li>
<li>AbbVie shares fell 0.1% to close at $189.95 on Tuesday.</li>
<li>Cerence shares gained 6.2% to settle at $12.07.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Long Ideas

News

Markets

Media

Trading Ideas

$BTC

ABBV

COIN

CRNC

Jim Cramer: This Health Care Stock Is A 'Winner,' Buy Bitcoin Instead Of Coinbase

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 10 years by 4.14% on an annualized basis producing an average annual return of 15.41%. Currently, Stryker has a market capitalization of $149.23 billion. 
Buying $100 In SYK: If an investor had bought $100 of SYK stock 10 years ago, it would be worth $424.37 today based on a price of $391.46 for SYK at the time of writing.
<h3>Stryker's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738686610_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Stryker 10 Years Ago Would Be Worth This Much Today

Disclosed in a recent SEC filing on January 30, Pierce, Group President at Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: Pierce, Group President at Stryker, made a strategic move by exercising stock options for 9,455 shares of SYK as detailed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000310764/000031076425000006//Archives/edgar/data/310764/000031076425000006/0000310764-25-000006-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $2,843,803.
During Friday's morning session, Stryker shares up by 0.87%, currently priced at $393.83. Considering the current price, Pierce's 9,455 shares have a total value of $2,843,803.
<h3>Unveiling the Story Behind Stryker</h3>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>Stryker's Economic Impact: An Analysis</h3>
Revenue Growth: Stryker's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 17.15%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 64.85%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Stryker's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.43.
</li>
</ul>
Debt Management: Stryker's debt-to-equity ratio is below the industry average at 0.59, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Stryker's P/E ratio of 50.31 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 6.66 is above industry norms, reflecting an elevated valuation for Stryker's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 27.39, Stryker's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000310764">Check Out The Full List Of Stryker's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Strategic Sale: James Andrew Pierce Decides To Exercise Options Worth $2.84M At Stryker

Disclosed in a recent SEC filing on January 30, Stiles, Group President at Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000310764/000031076425000007//Archives/edgar/data/310764/000031076425000007/0000310764-25-000007-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Stiles, Group President at Stryker, a company in the Health Care sector, just exercised stock options worth 10,210 shares of SYK stock with an exercise price of $93.06.
The Friday morning market activity shows Stryker shares up by 0.87%, trading at $393.83. This implies a total value of $3,070,887 for Stiles's 10,210 shares.
<h3>All You Need to Know About Stryker</h3>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>Stryker: A Financial Overview</h3>
Revenue Growth: Stryker's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 17.15%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 64.85%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Stryker's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 1.43.
</li>
</ul>
Debt Management: Stryker's debt-to-equity ratio is below the industry average. With a ratio of 0.59, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 50.31, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 6.66, Stryker's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 27.39, Stryker presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000310764">Check Out The Full List Of Stryker's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Move: Spencer S Stiles Exercises Options, Realizing $3.07M At Stryker

Goldman Sachs analyst David Roman maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Neutral and raises the price target from $384 to $427.

Price Target

Analyst Ratings

Goldman Sachs Maintains Neutral on Stryker, Raises Price Target to $427

Truist Securities analyst Richard Newitter maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Hold and raises the price target from $409 to $413.

Truist Securities Maintains Hold on Stryker, Raises Price Target to $413

Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Stryker, presenting an average target of $435.5, a high estimate of $450.00, and a low estimate of $409.00. Marking an increase of 5.56%, the current average surpasses the previous average price target of $412.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1738184437_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Stryker. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$435.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$435.00</td>
<td>$427.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$445.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$440.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Kyle Rose</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$435.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$442.00</td>
<td>$442.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$425.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$442.00</td>
<td>$442.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$409.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$442.00</td>
<td>$409.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$411.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$425.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$427.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$445.00</td>
<td>$370.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stryker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Stryker compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Stryker's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Stryker's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SYK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Stryker analyst ratings.</a>
<h2>Unveiling the Story Behind Stryker</h2>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>Understanding the Numbers: Stryker's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Stryker's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.92%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Stryker's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 15.18%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.18%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Stryker's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 2.01%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.77, Stryker faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Stryker Through 14 Analysts

Wall Street analysts rerated Stryker Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) Wednesday after the company&#8217;s fourth-quarter print.
Stryker <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43286955/stryker-reports-2024-operating-results-and-2025-outlook" rel="noreferrer noopener">reported quarterly earnings</a> of&nbsp;$4.01&nbsp;per share, which beat the analyst consensus estimate of&nbsp;$3.87. The company reported quarterly sales of&nbsp;$6.44 billion, up by 10.7%,&nbsp;which beat the analyst consensus estimate of&nbsp;$6.36 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43310211/nasdaq-q4-earnings-10-revenue-growth-strategic-wins-and-strong-financial-tech-performance-sets-2025-expense-and-tax-guidance" rel="noreferrer noopener">Nasdaq Touts 10% Revenue Growth In Q4, Sets 2025 Expense And Tax Guidance</a>
Several analysts rerated the stock:
<ul>
<li>Stifel analyst Rick Wise maintained Stryker with a Buy and raised the <a href="https://www.benzinga.com/quote/SYK/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $400 to $440</a>.</li>
<li>Needham analyst Mike Matson reiterated Stryker with a Buy and a $442 price target.</li>
<li>RBC Capital analyst Shagun Singh Chadha maintained a Buy on Stryker and set a price target of $435.</li>
<li>Piper Sandler analyst Matthew O&#8217;Brien reiterated a Buy on Stryker with a price target of $420.</li>
</ul>
Stifel: Stryker delivered an excellent finish to the year 2024, turning in better-than-expected fourth-quarter performance across multiple key metrics: sales, margins, and EPS. Impressively, this above consensus performance bookended the company&#8217;s fourth consecutive double-digit organic sales growth year.
Simultaneous with the earnings release, Stryker also announced the planned retirement of long-time CFO Glenn Boehnlein and the imminent sale of the lower-growth Spine Implant business.
Without offering transaction proceed specifics, Stryker highlighted an anticipated first-half U.S. Spine Implant close with international divestitures to follow. Historically growing below the corporate average sales growth rate, Wise remains inclined to view the Spine Implant sale positively for Stryker.
Wise projected first-quarter revenue of $5.67 billion and EPS of $2.68.
Needham: Stryker&#8217;s fourth-quarter revenue and EPS beat consensus, and management provided 2025 revenue guidance that bracketed consensus and EPS guidance above consensus.
Stryker again saw broad-based strength across most of its businesses, driven by substantial procedure volumes, new products, and its capital equipment backlog. Organic sales growth slowed to 10.2% in the fourth quarter from 11.5% in the third quarter.
Stryker&#8217;s gross margin was up 140 bps Y/Y, but its operating margin was up 200 bps Y/Y. Stryker also announced the retirement of CFO Glenn Boehnlein and divesting its spine implant business, with the deal expected to close in the first half. Matson noted that 2025 guidance is likely to prove conservative.
Matson projected first-quarter revenue of $5.64 billion and EPS of $2.80.
RBC Capital: Stryker delivered a strong exit to 2024, beating fourth-quarter consensus estimates, and issued a strong initial 2025 guide for organic sales, margins, and EPS growth.
Notably, Stryker is taking steps to improve its WAMGR with the sale of its spinal implant assets and the acquisition of NARI. After today&#8217;s call, Chadha is bullish on Stryker&#8217;s growth durability, the trajectory for operating margin expansion, and EPS growth.
Chadha projected first-quarter revenue of $5.65 billion and EPS of $2.70.
Piper Sandler: Stryker also reported fourth-quarter results and guided for fiscal 2025. Both were ahead of Street expectations. More specifically, Stryker is guiding organic revenue growth of 8%-9%, which O&#8217;Brien noted as achievable, if not conservative.
Additionally, the company announced that their long-time CFO, Glenn Boehnlein, will retire and be replaced by Preston Wells (which impressed O&#8217;Brien).
Finally, Stryker is selling its U.S. spinal implants business and expects to close its acquisition of NARI by the end of next month, which collectively should improve its addressable WAMGR.
When putting these two updates together with continued strong performance from the core business, O&#8217;Brien noted Stryker is set up to continue delivering some of the best growth in large-cap, diversified med tech, which keeps the analyst constructive on the name.
O&#8217;Brien projected first-quarter revenue of $5.69 billion and EPS of $2.71.
Price Action: SYK stock is down 0.20% at $394.38 at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43309111/adp-q2-earnings-revenue-and-eps-beat-record-client-satisfaction-and-strong-hcm-demand-reaffirms-fy25-outlook" target="_blank" rel="noreferrer noopener">ADP Q2 Earnings: Revenue And EPS Beat, Record Client Satisfaction and Strong HCM Demand, Reaffirms FY25 Outlook</a></li>
</ul>
Image via Stryker

Analyst Color

Reiteration

Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth

RBC Capital analyst Shagun Singh maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and raises the price target from $425 to $435.

RBC Capital Maintains Outperform on Stryker, Raises Price Target to $435

Wells Fargo analyst Larry Biegelsen maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Overweight and raises the price target from $427 to $435.

Wells Fargo Maintains Overweight on Stryker, Raises Price Target to $435

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Truist Securities raised the price target for Tempur Sealy International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) from $63 to $69. Truist Securities analyst Keith Hughes maintained a Buy rating. Tempur Sealy shares closed at $60.62 on Tuesday. <a href="https://www.benzinga.com/quote/TPX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) price target from $152 to $150. JP Morgan analyst Bill Peterson maintained an Overweight rating. Nucor shares closed at $126.55 on Tuesday. <a href="https://www.benzinga.com/quote/NUE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank cut the price target for NextEra Energy Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) from $15 to $12. Scotiabank analyst Andrew Weisel maintained a Sector Perform rating. NextEra Energy Partners shares closed at $11.83 on Tuesday. <a href="https://www.benzinga.com/quote/NEP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Argus Research raised the price target for Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from $280 to $305. Argus Research analyst John Staszak maintained a Buy rating. Royal Caribbean Cruises shares closed at $265.25 on Tuesday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel boosted Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) price target from $400 to $450. Stifel analyst Rick Wise maintained a Buy rating. Stryker shares settled at $395.15 on Tuesday. <a href="https://www.benzinga.com/quote/SYK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) price target from $21 to $19. B of A Securities analyst Michael McGovern maintained a Buy rating. Lyft shares closed at $13.96 on Tuesday. <a href="https://www.benzinga.com/quote/LYFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan lifted RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) price target from $140 to $150. JP Morgan analyst Seth Seifman maintained an Overweight rating. RTX shares closed at $128.35 on Tuesday.  <a href="https://www.benzinga.com/quote/RTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted the price target for F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) from $285 to $360. Needham analyst Matt Dezort maintained a Buy rating. F5 shares settled at $269.72 on Tuesday. <a href="https://www.benzinga.com/quote/FFIV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo boosted Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) price target from $127 to $135. Wells Fargo analyst Stephen Baxter maintained an Equal-Weight rating. Cardinal Health shares closed at $126.27 on Tuesday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays increased Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) price target from $119 to $124. Barclays analyst Jeffrey Bernstein maintained an Overweight rating. Starbucks shares closed at $100.41 on Tuesday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43301090/how-to-earn-500-a-month-from-meta-platforms-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Meta Platforms Stock Ahead Of Q4 Earnings</a></li>
</ul>

FFIV

LYFT

SBUX

Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesday

JP Morgan analyst Robbie Marcus maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Overweight and raises the price target from $420 to $445.

JP Morgan Maintains Overweight on Stryker, Raises Price Target to $445

Stifel analyst Rick Wise maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $400 to $440.

Stifel Maintains Buy on Stryker, Raises Price Target to $440

Canaccord Genuity analyst Kyle Rose maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $420 to $435.

Canaccord Genuity Maintains Buy on Stryker, Raises Price Target to $435

Needham analyst Mike Matson reiterates Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and maintains $442 price target.

Needham Reiterates Buy on Stryker, Maintains $442 Price Target

U.S. stock futures were mixed on Wednesday ahead of the crucial earnings from key U.S. technology companies and the Federal Reserve&#8217;s expected pause on rate cuts. Futures of all benchmark indices were up, except Dow Jones.
Traders will be waiting for cues from Fed Chairman Jerome Powell&#8216;s speech to navigate the markets as President Donald Trump slowly unveils his plans on tariffs, deregulation, and immigration, among other economic developments.
The 10-year Treasury yield stood at 4.52%, while the two-year yield was at 4.19%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 99.5% chance that the Federal Reserve will keep interest rates unchanged later today. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.40%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.09%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.04%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.21%</td>
</tr>
</tbody>
</table>
</figure>
Both the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) were trading higher in premarket on Wednesday. SPY was up by 0.11% to $605.19, while QQQ gained 0.45% to $524.22, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Markets <a href="https://www.benzinga.com/news/earnings/25/01/43295848/nasdaq-jumps-2-after-nvidia-other-tech-stocks-bounce-back-from-deepseek-hit-greed-index-remains-in-fear-zone">rebound</a> after Monday&#8217;s DeepSeek-triggered crash. Nasdaq surged 2%, with Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) reclaiming some ground.
Mixed earnings reports saw General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) beat expectations while Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) fell over 9%.
Economic data showed declining durable goods orders and rising home prices. Tech led the recovery, while utilities and real estate lagged. Dow, S&amp;P 500, and Nasdaq all closed higher.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>2.03%</td>
<td>19,733.59</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.92%</td>
<td>6,067.70</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.31%</td>
<td>44,850.35</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.21%</td>
<td>2,288.86</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
According to Ed Yardeni and Eric Wallerstein from Yardeni Research, "U.S. stock market quickly confirmed our view that DeepSeek is a positive for the proliferation of AI, which should boost productivity and economic growth, especially in the U.S."
They expect that fourth-quarter earnings will continue to positively surprise the market. The Fed is likely to pause rate cuts due to better-than-expected economic growth, they said.
"The big companies will benefit from increased AI demand and cheaper internal costs. DeepSeek increases our confidence in our technology-driven, productivity-led Roaring 2020s scenario," they added.
Justin Wolfers, who is a professor at the University of Michigan and a senior fellow at the Brookings Institution and Peterson Institute told CNN that the Fed's job is not to surprise people.
"Watching the Fed is going to be a little bit boring for a few months because they're like the rest of us. They're gonna watch and see what happens. With inflation coming back down toward the Fed's target, you would normally expect to see the Fed continuing to bring interest rates back to normal," he said.
Wolfers said that all eyes are on Donald Trump's decision on tariffs and how the Fed will respond to it. According to him, the Fed could view the rise in inflation caused by tariffs as a "blip in inflation," and decide not to react or it could be worried that tariffs may have a real effect on inflation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Fed meets tomorrow. Here&#39;s my Fed preview. <a href="https://t.co/YZTkoEpRum">pic.twitter.com/YZTkoEpRum</a>
&mdash; Justin Wolfers (@JustinWolfers) <a href="https://twitter.com/JustinWolfers/status/1883962385758896620?ref_src=twsrc%5Etfw">January 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Wednesday:
<ul>
<li>On Wednesday, December's data for advanced U.S. trade balance in goods, advanced retail inventories, and advanced wholesale inventories will be released at 8:30 a.m., ET.</li>
<li>The FOMC interest-rate decision will be out at 2:00 p.m. and Chairman Jerome Powell will address a press conference at 2:30 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) was down 0.49% in the premarket on Wednesday ahead of its earnings to be released after the closing bell. Analysts expect it to report quarterly earnings of 74 cents per share on revenue of $27.13 billion.</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) was down 0.16% as Wall Street expects it to report earnings of $3.12 per share on revenue of $68.80 billion, after the closing bell.</li>
<li>Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) was up 0.68% in the premarket ahead of its earnings to be released after the closing bell. Analysts expect it to report quarterly earnings of $6.77 per share on revenue of $46.99 billion.</li>
<li>ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) was up 7.07% after its revenue and earnings per share beat analyst estimates.</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) was down 0.39% despite posting better-than-expected first-quarter financial results. However, the company suspended its guidance for fiscal year 2025 last quarter, citing the company's "CEO transition coupled with the current state of the business."</li>
<li>Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) was down 1.30% after it reported better-than-expected earnings results but announced the retirement of its CFO Glenn Boehnlein.</li>
<li>60 Degrees Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) was up 81.63% as it received IRB approval of Phase II study to examine tafenoquine for chronic babesiosis.</li>
<li>Silexion Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) was up 37.04% after reporting new preclinical data on Tuesday for SIL-204, showing significant tumor reduction in pancreatic cancer models.</li>
<li>Banzai International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) was up 12.80% following its recent announcement of the acquisition of Act-On Software.</li>
<li>Manhattan Associates Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) was down 24.77% following soft FY25 guidance.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.99% to hover around $73.04 per barrel.
The gold spot index was down by 0.22% to $2,757.49 per ounce. The Dollar Index was up 0.22% at 108.105 level.
Asian markets were mostly higher on Wednesday except China's CSI 300 index. Australia's ASX 200, Japan's Nikkei 225, South Korea's Kospi, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex rose. European markets were also higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43295664/nvidia-supplier-asml-beats-q4-earnings-as-ceo-says-ai-is-key-driver-for-growth-is-it-a-buy-sell-or-hold-heres-what-technical-analysis-suggest">Nvidia Supplier ASML Beats Q4 Earnings Estimates, CEO Says &#8216;AI Is Key Driver For Growth:&#8217; Buy, Sell, Or Hold? Here&#8217;s What Technical Analysis Suggests</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Macro Economic Events

Futures

Economics

Federal Reserve

Pre-Market Outlook

ASML

BNZI

MANH

MSFT

NVDA

SLXN

SXTP

TSLA

US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings

With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) to report quarterly earnings at 74 cents per share on revenue of $27.13 billion after the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Tesla shares fell 0.4% to $396.65 in after-hours trading.</li>
<li>Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) reported better-than-expected first-quarter financial results. The company suspended its guidance for fiscal year 2025 last quarter, citing the company&#8217;s &#8220;CEO transition coupled with the current state of the business.&#8221; Niccol took over as chief executive of Starbucks in September. Starbucks shares gained 0.4% to $100.79 in the after-hours trading session.</li>
<li>Analysts are expecting Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) to post quarterly earnings at $3.12 per share on revenue of $68.80 billion. The company will release earnings after the markets close. Microsoft shares fell 0.1% to $446.70 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Stryker Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) reported upbeat earnings for its fourth quarter. The company posted quarterly earnings of $4.01 per share which beat the analyst consensus estimate of $3.87 per share. The company reported quarterly sales of $6.44 billion which beat the analyst consensus estimate of $6.36 billion. The company also announced the retirement of its CFO Glenn Boehnlein. Stryker shares fell 0.8% to $392.00 in the after-hours trading session.</li>
<li>Analysts expect Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) to post quarterly earnings at $6.77 per share on revenue of $46.99 billion after the closing bell. Meta shares gained 0.5% to $677.98 in after-hours trading.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/25/01/43266082/jim-cramer-coterra-energy-is-the-cheapest-natural-gas-company-recommends-buying-this-financial-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/01/43266082/jim-cramer-coterra-energy-is-the-cheapest-natural-gas-company-recommends-buying-this-financial-stock">Jim Cramer Recommends Buying &#8216;Fabulous&#8217; BlackRock, Calls Coterra Energy The &#8216;Cheapest&#8217; Natural Gas Company</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Tesla, Starbucks And 3 Stocks To Watch Heading Into Wednesday

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) just disclosed its Q4 earnings on Tuesday, January 28, 2025 at 04:05 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Stryker beat estimated earnings by 4.0%, reporting an EPS of $4.01 versus an estimate of $3.87.
Revenue was up $621.00 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.1 in the last quarter, resulting in a 1.0% increase share price change the following day.
Here's a look at Stryker's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.77</td>
<td>2.79</td>
<td>2.35</td>
<td>3.27</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.87</td>
<td>2.81</td>
<td>2.50</td>
<td>3.46</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>5.37B</td>
<td>5.41B</td>
<td>5.10B</td>
<td>5.60B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>5.49B</td>
<td>5.42B</td>
<td>5.24B</td>
<td>5.82B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Stryker management provided guidance for FY 2025, expecting earnings between $13.45 and $13.7 per share.
To track all earnings releases for Stryker <a href="https://www.benzinga.com/quote/SYK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stryker Earnings Report: Q4 Overview

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) released its Q4 earnings on Tuesday, January 28, 2025 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Stryker beat estimated earnings by 4.0%, reporting an EPS of $4.01 versus an estimate of $3.87.
Revenue was up $621.00 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company beat on EPS by $0.1, leading to a 1.0% increase share price change the next day.
Here's a look at Stryker's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.77</td>
<td>2.79</td>
<td>2.35</td>
<td>3.27</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.87</td>
<td>2.81</td>
<td>2.50</td>
<td>3.46</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>5.37B</td>
<td>5.41B</td>
<td>5.10B</td>
<td>5.60B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>5.49B</td>
<td>5.42B</td>
<td>5.24B</td>
<td>5.82B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Stryker management provided guidance for FY 2025, expecting earnings between $13.45 and $13.7 per share.
To track all earnings releases for Stryker <a href="https://www.benzinga.com/quote/SYK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stryker Earnings Review: Q4 Summary

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) reported its Q4 earnings results on Tuesday, January 28, 2025 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Stryker beat estimated earnings by 4.0%, reporting an EPS of $4.01 versus an estimate of $3.87.
Revenue was up $621.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company beat on EPS by $0.1 in the previous quarter, leading to a 1.0% increase share price change the next day.
Here's a look at Stryker's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.77</td>
<td>2.79</td>
<td>2.35</td>
<td>3.27</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.87</td>
<td>2.81</td>
<td>2.50</td>
<td>3.46</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>5.37B</td>
<td>5.41B</td>
<td>5.10B</td>
<td>5.60B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>5.49B</td>
<td>5.42B</td>
<td>5.24B</td>
<td>5.82B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Stryker management provided guidance for FY 2025, expecting earnings between $13.45 and $13.7 per share.
To track all earnings releases for Stryker <a href="https://www.benzinga.com/quote/SYK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stryker Earnings Analysis: Q4 Recap

Franklin Rising Dividends Fund Q4 2024 Commentary

Lake Street analyst Brooks O'Neil notes that Stryker (SYK) announced a definitive agreement for the sale of its U.S. spinal implants business and p...

Alphatec likely to benefit as Stryker exits spinal implants, says Lake Street

Truist raised the firm's price target on Stryker (SYK) to $413 from $409 and keeps a Hold rating on the shares. The company remains a top-tier MedT...

Stryker price target raised to $413 from $409 at Truist

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Stryker (SYK – Research Report), with a price target of $435.00....

Stryker (SYK) Gets a Buy from TD Cowen

Argus analyst David Toung raised the firm's price target on Stryker (SYK) to $450 from $410 and keeps a Buy rating on the shares. Argus expects a s...

Stryker price target raised to $450 from $410 at Argus

New insider activity at Stryker ( ($SYK) ) has taken place on February 4, 2025. Director Ronda Stryker has made a significant move by selling 201,3...

Major Stock Sell-Off by Stryker Director Shakes Up Market!

Inari Medical ticks higher after HSR waiting period expires in Stryker deal

Stryker declares $0.84 dividend

Model Portfolio For Capital Appreciation, February '25

Model Portfolio For Capital Appreciation, February 2025

AAPL

AMZN

ATEC

AVGO

BMYMP

COST

CRWD

CTRA

NARI

TXRH

VCTR

WFCNP

Screenshot 2024-09-30 at 5.38.54 PM

Biotech

Movers & Shakers

General

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Screenshot 2024-03-18 at 5.30.26 PM

Health Care

MGRM

Monogram Orthopaedics (NASDAQ: MGRM) Aims To Overcome Robot Shortcomings With Its Advanced Solution

Press Releases

Why Healthcare Providers Are Increasingly Trusting Artificial Intelligence for Detection & Diagnosis

Stryker to announce financial results for its fourth quarter and full year 2024

Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment

INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inari Medical, Inc. - NARI

Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.

Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer

Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business

Stryker reports 2024 operating results and 2025 outlook

RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office

Dividends

Stryker declares an $0.84 per share quarterly dividend

AVAI

PEGA

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Inari Medical

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Comments

Stryker

空売り

Stryker (NYSE:SYK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル